In congenital hemophilia, in patients who receive exogenous FVIII, most inhibitors are categorized as “type 1,” resulting in linear inactivation when plotted against the inhibitor’s plasma concentration [59, 67–69]. The gene discussed is F8; the disease is hemophilia.